Compare Amgen, Inc. (AMGN) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Banco Santander SA — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Banco Santander SA trades at $13.75 (market cap $197.91B). The key difference: Amgen, Inc. and Banco Santander SA are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | SAN | |
|---|---|---|
Market Cap | $196.12B | $197.91B |
Sector | Health | Financials |
52-Week High | $388.16 | $14.37 |
52-Week Low | $271.18 | $8.31 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Banco Santander (SAN) trades at $13.87, up 0.58% today, with a bullish technical signal from moving averages. The company reported $14.10B net income for 2025 with a 23.49% margin, though recent quarterly EPS results missed expectations. Analyst consensus is 64% buy, supported by news of Santander becoming Spain's most valuable company and its AI-driven efficiency initiatives.
Outlook is cautiously optimistic with strong profitability and strategic acquisitions, but risks include consecutive EPS misses, a significant net cash outflow trend, and regulatory scrutiny in Spain. The stock's valuation appears reasonable with a P/E of 13.78, offering potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
